These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 22393098

  • 1. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM.
    J Clin Oncol; 2012 Apr 01; 30(10):1064-71. PubMed ID: 22393098
    [Abstract] [Full Text] [Related]

  • 2. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH.
    J Med Econ; 2014 Jan 01; 17(1):32-42. PubMed ID: 24028444
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1078-85. PubMed ID: 23873405
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK, Wong WW, Trudeau ME, Chan KK.
    Breast Cancer Res Treat; 2015 Feb 07; 150(1):169-80. PubMed ID: 25694355
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH.
    Value Health; 2009 Feb 07; 12(2):217-25. PubMed ID: 18673353
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M.
    Clin Ther; 2010 Feb 07; 32(2):311-26. PubMed ID: 20206789
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC.
    J Clin Oncol; 2008 Jan 10; 26(2):290-6. PubMed ID: 18182670
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.
    Gynecol Oncol; 2014 Jun 10; 133(3):446-53. PubMed ID: 24657302
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C, Rayson D, Younis T.
    Support Care Cancer; 2016 Jan 10; 24(1):387-394. PubMed ID: 26081595
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb 10; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.
    Value Health; 2011 Jun 10; 14(4):465-74. PubMed ID: 21669371
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH, Lalla A, Barron RL, Dubois RW.
    Clin Ther; 2009 May 10; 31(5):1092-104. PubMed ID: 19539110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.